7 The treatment effect increased through four weeks resulting in a median BCVA improvement of 12.5 eye chart letters and median Central Retinal Thickness on OCT improvement of 120 microns, pooled across all three dose levels. At twelve weeks after the single dose, a median BCVA improvement of nine eye chart letters (almost two lines of vision) and median OCT improvement of 121 microns were observed, pooled across all three dose levels. Improvements in vision and retinal thickness after a single-dose of KSI-301 through 12 weeks were as follows: To help contextualize our results, the figure below shows example color retinal photographs and OCT images from both normal patients and a patient with DME who did not participate in our study. The extent of pathology seen in patients with DME is readily visible when comparing to the normal photograph.